Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Adaptimmune Therapeutics Plc (ADAP) Insider Trading Activity
Healthcare • Biotechnology • 449 employees
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Total Value
-$105,249.98
Total Shares
-181,192
Average Trade Value
-$6,191.18
Most Active Insider
Rawcliffe Adrian
Total Activity: $52,413
Largest Single Transaction
$17,773
by Rawcliffe Adrian on Jan 17, 2025
30-Day Activity
17 Transactions
Volume: 181,192 shares
Value: $105,250
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Executive Officer
Director, Officer
|
Jan 17, 2025 | 30,601 | $17,773 | 44,327 (-69.0%) | Sale | |
|
Chief Operating Officer
Officer
|
Jan 17, 2025 | 5,584 | $3,243 | 7,510 (-74.4%) | Sale | |
|
Chief Patient Supply Officer
Officer
|
Jan 17, 2025 | 5,584 | $3,243 | 7,510 (-74.4%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 17, 2025 | 5,584 | $3,243 | 7,510 (-74.4%) | Sale | |
|
Chief Commercial Officer
Officer
|
Jan 15, 2025 | 12,991 | $7,467 | 18,421 (-70.5%) | Sale | |
|
Chief Patient Supply Officer
Officer
|
Jan 15, 2025 | 9,803 | $5,635 | 13,756 (-71.3%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Jan 15, 2025 | 29,096 | $16,724 | 41,582 (-70.0%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 15, 2025 | 9,803 | $5,635 | 13,756 (-71.3%) | Sale | |
|
Chief Operating Officer
Officer
|
Jan 15, 2025 | 9,803 | $5,635 | 13,756 (-71.3%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Jan 13, 2025 | 17,934 | $10,543 | 25,711 (-69.8%) | Sale | |
|
Chief Patient Supply Officer
Officer
|
Jan 13, 2025 | 5,471 | $3,216 | 7,623 (-71.8%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 13, 2025 | 4,268 | $2,509 | 5,845 (-73.0%) | Sale | |
|
Chief Medical Officer
Officer
|
Jan 13, 2025 | 8,124 | $4,776 | 11,516 (-70.5%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Jan 13, 2025 | 12,539 | $7,372 | 17,801 (-70.4%) | Sale | |
|
Chief Patient Supply Officer
Officer
|
Jan 13, 2025 | 4,268 | $2,509 | 5,845 (-73.0%) | Sale | |
|
Chief Operating Officer
Officer
|
Jan 13, 2025 | 5,471 | $3,216 | 7,623 (-71.8%) | Sale | |
|
Chief Operating Officer
Officer
|
Jan 13, 2025 | 4,268 | $2,509 | 5,845 (-73.0%) | Sale |